Abstract:The global prevalence of head and neck malignancies positions them as the sixth most common form of cancer, with the head and neck squamous cell carcinoma (HNSCC) representing the predominant histological subtype. Despite advancements in multidisciplinary approaches and molecular targeted therapies, the therapeutic outcomes for HNSCC have only marginally improved, particularly in cases of recurrent or metastatic HNSCC (R/MHNSCC). This situation underscores the critical necessity for the development of innovative therapeutic strategies. Such strategies are essential not only to enhance the efficacy of HNSCC treatment but also to minimize the incidence of associated complications, thus improving overall patient prognosis. Cancer immunotherapy represents a cutting-edge cancer treatment that leverages the immune system for targeting and destroying cancer cells. It's applied to multiple cancers, including melanoma and lung cancer, offering precision, adaptability, and the potential for long-lasting remission through immune memory. It is observed that while HNSCC patients responsive to immunotherapy often experience prolonged therapeutic benefits, only a limited subset demonstrates such responsiveness. Additionally, significant clinical challenges remain, including the development of resistance to immunotherapy. The biological characteristics, dynamic inhibitory changes, and heterogeneity of the tumor microenvironment (TME) in HNSCC play critical roles in its pathogenesis, immune evasion, and therapeutic resistance. This review aims to elucidate the functions and mechanisms of anti-tumor immune cells and extracellular components within the HNSCC TME. It also introduces several immunosuppressive agents commonly utilized in HNSCC immunotherapy, examines factors influencing the effectiveness of these treatments, and provides a comprehensive summary of immunotherapeutic strategies relevant to HNSCC.

Insights into Nanomedicine for Immunotherapeutics in Squamous Cell Carcinoma of the Head and Neck

Advances in Nonsurgical Treatment of Head and Neck Squamous Cell Carcinoma

Nanoparticle-Based Targeted Therapeutics In Head-And-Neck Cancer

Revolutionizing head and neck squamous cell carcinoma treatment with nanomedicine in the era of immunotherapy

Nanomedicine in HNSCC therapy-a challenge to conventional therapy

Cancer Nanomedicine Meets Immunotherapy: Opportunities and Challenges

Advances in nanomedicine for head and neck cancer.

The emerging nanomedicine-based technology for non-small cell lung cancer immunotherapy: how far are we from an effective treatment.

Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma

The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC)

Nanotechnologies for Enhancing Cancer Immunotherapy

Nano-immunotherapy for Lung Cancer

New Advances in the Therapeutic Strategy of Head and Neck Squamous Cell Carcinoma: A Review of Latest Therapies and Cutting-Edge Research

Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma

Recent Advance in Nanomaterials for Cancer Immunotherapy

Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma

Nanoengineered Targeting Strategy for Cancer Immunotherapy

Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy

Nanomedicine Sheds New Light on Cancer Immunotherapy.

Nanomaterial-based cancer immunotherapy: enhancing treatment strategies

The role of nanotherapy in head and neck squamous cell carcinoma by targeting tumor microenvironment